were no participants having an adverse event (AE) leading to discontinuation of BLV and no serious AEs attributed to BLV treatment.
Conclusion: Results at Week 48 demonstrate that treatment with BLV resulted in a significantly greater combined response compared to control. Monotherapy with BLV was safe and well tolerated.

Friday 24 June

General Session II

GS007

Transcatheter arterial chemoembolization (TACE) followed by conformal radiotherapy versus TACE alone for hepatocellular carcinoma: a western controlled trial

Cyrille Feray[1], Loic Campion[2], Isabelle Mabile-Archambeaud[3], Philippe Mathurin[4], Xavier Mirabel[5], Emmanuel Rio[2], Jean-Pierre Bronowicki[6], Yann Touchefeu[3], Jérôme Gournay[3], Agnès Rode[7], Francoise Mornex[8], Philippe Merle[9]. *[1]Centre Hepato Biliaire, Villejuif, France; [2]CRLCC, Nantes, France; [3]IMAD, Nantes, France; [4]Hepatology, Lille, France; [5]CRLCC, Lille, France; [6]Hepatology, Nancy, France; [7]Radiology, Lyon, France; [8]Radiotherapy, Lyon, France; [9]Hepatology, Lyon, France*
Email: cyrille.feray@gmail.com

Background: Transarterial chemoembolization (TACE) is a recommended treatment for patients with hepatocellular carcinoma and no possible ablative therapy. We aimed to compare the efficacy and safety of a combination of one TACE followed by external conformal radiotherapy (CRT) to the two TACE procedure.
Methods: TACERTE was an open-labelled randomized controlled trial with a 1:1 allocation rate. Patients had a mean age of 70 y, were male in 86 %. Etiology was HCV in 13%, HBV in 2% and alcohol for the others. The primary end point was progression-free survival (PFS; Kaplan-Meier analysis) in the intention-to-treat population. The typical schedule of CRT was 54 gy in 18 sessions. DC beads were used for TACE in 82/120 (68%). Study registered in clinical trial.gov (NCT01300143).
Results: Among the 120 randomized patients, 64 were in the arm TACE alone and 56 in the TACE-CRT arm. 91/120 (76%) did not have received any previous therapy. Eight patients (4 in each arm) had a rapid tumoral progression and did not received the planned therapy. The PFS at 12 and 18 months was 53% and 32 % in the TACE and CRT group and 59% and 30 % in TACE alone group (HR = 1.07; 95% CI: [0.65–1.76]-p = 0.78). A centralized blinded review of imaging was possible in 95 patients (79%) and confirmed the absence of significant differences between the two arms. The overall survival (OS) at 12, 18 and 60 months was 69%, 57% and 15% in the TACE and CRT group and 81%, 75% and 17% in the TACE alone group (HR = 1.23–95%CI: [0.83–1.82]-p = 0.297). The median OS was 22 months (95%CI:[15.7–26.2]) in the TACE-CRT arm and 30 months (95% IC:[23–35]) in the other. The cumulated number of grade III–IV adverse events (AE) was 83 in the TACE and CRT group and 59 in the TACE alone group. A propensity score analysis demonstrated that exposure to TACE and CRT was associated to more AE.



Conclusion: In contrast with the results of previous eastern randomized trials, this first western randomized controlled trial demonstrates that compared to the conventional TACE, the combination of TACE followed by CRT procedure has no positive effect on the PFS or the OS in patients with unresectable HCC.
Funding: Programme Hospitalier de Recherche Clinique" (PHRC) in 2009 (Institut National du Cancer).

GS008

The global burden of liver cancer (LC) and chronic liver diseases (CLD) is driven by non-alcoholic steatohepatitis (NASH) and alcohol liver disease (ALD)

James Paik[1,2], Linda Henry[1,2,3], Youssef Younossi[3], Janus Ong[3,4], Saleh Alqahtani[3,5,6], Zobair Younossi[1,2,7]. *[1]Inova Health System, Center for Liver Diseases, Department of Medicine; [2]Betty and Guy Beatty Center for Integrated Research, IHS; [3]Center for Outcomes Research in Liver Disease; [4]University of the Philippines, College of Medicine; [5]Johns Hopkins Medical Center; [6]King Faisal Specialist Hospital and Research Center; [7]Inova Health System, Medicine Service Line*
Email: zobair.younossi@inova.org

Background and aims: Although chronic viral hepatitis B and C (CHB and CHC) and ALD have been the main drivers of burden of chronic liver disease (CLD) and liver cancer (LC), NASH has recently become more prominent. **Aim:** To assess changes in the global prevalence, incidence, mortality and morbidity [disability-adjusted life-years (DALYs)] related to LC and CLD according to the etiology of CLD and 21 GBD regions of the world.
Method: The data was obtained from the Global Burden of Disease Study 2019 (GBD 2019). Incidence, prevalence, mortality and DALYs were calculated. Annual percent change (APC) was calculated by using Joinpoint regression program, National Cancer Institute.
Results: In 2019 globally, the prevalence, incidence, mortality and DALYs from liver disease was 1.69 billion (LC 0.04% and CLD 99.96%), 2.59 million (LC 20.7% and CLD 79.3%); 1.95 million (LC 24.8% and CLD 75.3%) and 58.7 million (LC 21.3% and CLD 78.7%). Over the last decade (2009 to 2019), there was +33.7% increase in prevalence of LC and +22.7% in the prevalence of CLD. Furthermore, there was +30.0% increase in the incidence of LC and +14.8% increase in the incidence of CLD. Finally, both deaths [LC (+27.2%) and CLD (+10.6%)] as well as DALYs [LC (+21.9%) and CLD (+5.1%)] increased.
During the past decade (2009–2019), the observed increases (APC = +1.33%) in global LC death rate (per 100, 000) were driven by NAFLD (from 0.36 to 0.45, APC = +2.47%), ALD (from 0.97 to 1.17, APC = +1.91%), HBV (from 2.25 to 2.48, APC = +0.21%) and HCV (from 1.64 to 1.83, APC = +1.12%) (Figure).
In contrast, between 2009 and 2019, the observed decreases (APC = –0.18%) in the global CLD death rate (per 100, 000) were driven by decrease in HBV (from 5.07 to 4.28, APC = –1.83%); while HCV (from